Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Always Active
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
ABRE Study - 36-month clinical outcomes

The ABRE Study shows clinically meaningful impact on quality of life through 36 months — even in the most complex patients.


Review cinical outcomes

47.5%

categorized as PTS patients

35.8%

of PTS patients presented with complete vein occlusion

112.4 mm

average lesion length

44.0%

patients with stents extending below inguinal ligament

Graph - 16.6% aDVT patients
Graph - 47.5% PTS patients
Graph - 36% NVL patients

Site and core lab data were used.
Source: Abre stent IFU.


See the device manual for detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu.

medtronic.eu/abre


© 2023 Medtronic. All rights reserved. UC202403554-cirse-2023-post-congress-eblast-for-abre-en-emea-10231629



Medtronic